Identification of Patients with Painful Diabetic Peripheral Neuropathy Who Have a Favorable Cost Profile with Pregabalin Treatment

Pain Practice

Volumn 13, Issue 6, 2013, Pages 476-484

  Udall, Margarita ^a   Mardekian, Jack ^a   Cabrera, Javier ^b  

^a PFIZER INC   (United States)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

Adherence; Diabetic neuropathy; Healthcare costs; Painful

Indexed keywords

AMITRIPTYLINE; DULOXETINE; GABAPENTIN; PREGABALIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PRESCRIPTION; PROPENSITY SCORE; SENSITIVITY ANALYSIS;

EID: 84880042935     PISSN: 15307085     EISSN: 15332500     Source Type: Journal    
DOI: 10.1111/papr.12008     Document Type: Article

References (41)

1. Sadosky A, McDermott AM, Brandenburg NA, Strauss M. A review of the epidemiology of painful diabetic peripheral neuropathy, post-herpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract. 2008;8:45-56.
2. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011. http://diabetes.niddk.nih.gov/DM/PUBS/statistics/#fast (accessed October 26, 2011).
3. Mohamadi A, Cooke DW. Type 2 diabetes mellitus in children and adolescents. Adolesc Med State Art Rev. 2010;21:103-119.
4. Benbow SJ, Wallymahmed ME, Macfarlane IA. Diabetic peripheral neuropathy and quality of life. Q J Med. 1998;91:733-737.
5. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract. 2000;47:123-128.
6. Gore M, Brandenburg N, Dukes E, Hoffman D, Tai K-S, Stacey B. Pain severity in diabetic peripheral neuropathy is associated with patient functioning, symptom levels of anxiety and depression, and sleep. J Pain Symptom Manage. 2005;30:374-385.
7. Tölle T, Xu X, Sadosky AB. Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns. J Diabetes Complications. 2006;20:26-33.
8. Stewart WF, Ricci JA, Chee E, Hirsch AG, Brandenburg N. Lost productive time and costs due to diabetes and diabetic neuropathic pain in the US workforce. J Occup Environ Med. 2007;49:672-679.
9. Gore M, Brandenburg N, Hoffman D, Tai K-S, Stacey B. Burden of illness in painful diabetic peripheral neuropathy (DPN): the patients' perspective. J Pain. 2006;7:892-900.
10. Ritzwoller DP, Ellis JL, Korner EJ, Hartsfield CL, Sadosky A. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting. Curr Med Res Opin. 2009;25:1319-1328.
11. Dworkin RH, Malone DC, Panarites CJ, Armstrong EP, Pham SV. Impact of postherpetic neuralgia and painful diabetic peripheral neuropathy on health care costs. J Pain. 2010;11:360-368.
12. Dworkin RH, Panarites CJ, Armstrong EP, Malone DC, Pham SV. Healthcare utilization in people with postherpetic neuralgia and painful diabetic peripheral neuropathy. J Am Geriatr Soc. 2011;59:827-836.
13. Dibonaventura MD, Cappelleri JC, Joshi AV. Association between pain severity and health care resource use, health status, productivity and related costs in painful diabetic peripheral neuropathy patients. Pain Med. 2011;12:799-807.
14. Taylor-Stokes G, Pike J, Sadosky A, Chandran A, Toelle T. Association of patient-rated severity with other outcomes in patients with painful diabetic peripheral neuropathy. Diabetes Metab Syndr Obes. 2011;4:401-408.
15. Argoff CE, Backonja MM, Belgrade MJ, et al. Consensus guidelines: treatment planning and options. Mayo Clinic Proc. 2006;81:S12-S25.
16. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;Epub ahead of print.
17. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758-1765.
18. Berger A, Dukes E, Edelsberg J, Stacey B, Oster G. Use of tricyclic antidepressants in older patients with diabetic peripheral neuropathy. Clin J Pain. 2007;23:251-258.
19. Gore M, Sadosky A, Leslie D, Sheehan AH. Selecting an appropriate medication for treating neuropathic pain in patients with diabetes: a study using the U.K. and Germany Mediplus databases. Pain Pract. 2008;8:253-262.
20. Wu N, Chen S, Boulanger L, Fraser K, Bledsoe SL, Zhao Y. Duloxetine compliance and its association with healthcare costs among patients with diabetic peripheral neuropathic pain. J Med Econ. 2009;12:192-202.
21. Chen SY, Wu N, Boulanger L, Fraser KA, Zhao Y. The relationship between average daily dose, medication adherence, and health-care costs among diabetic peripheral neuropathic pain patients initiated on duloxetine therapy. Pain Pract. 2010;10:530-539.
22. Zhao Y, Sun P, Watson P. Medication adherence and healthcare costs among patients with diabetic peripheral neuropathic pain initiating duloxetine versus pregabalin. Curr Med Res Opin. 2011;27:785-792.
23. Sanchez RJ, Mardekian J, Cappelleri JC. Therapeutic and sub-therapeutic dosing of pregabalin: medication adherence, healthcare resource utilization, and costs. Am J Pharm Benefits. 2012;
24. Udall M, Harnett J, Mardekian J. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy. J Med Econ. 2012;15:361-370.
25. Margolis JM, Johnston SS, Chu BC, et al. Effects of a Medicaid prior authorization policy for pregabalin. Am J Manag Care. 2009;15:e95-102.
26. Margolis JM, Cao Z, Onukwugha E, et al. Healthcare utilization and cost effects of prior authorization for pregabalin in commercial health plans. Am J Manag Care. 2010;16:447-456.
27. Fick DM, Mion LC, Beers MH, Waller JL. Health outcomes associated with potentially inappropriate medication use in older adults. Res Nurs Health. 2008;31:42-51.
28. Gore M, Tai KS, Zlateva G, Bala Chandran A, Leslie D. Clinical characteristics, pharmacotherapy, and healthcare resource use among patients with diabetic neuropathy newly prescribed pregabalin or gabapentin. Pain Pract. 2011;11:528-539.
29. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
30. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
31. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
32. Semel D, Murphy TK, Zlateva G, Cheung R, Emir B. Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies. BMC Fam Pract. 2010;11:85.
33. Ihaka R, Gentleman R. A language for data analysis and graphics. J Comput Graph Stat. 1996;5:299-314.
34. Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults. Results of a US consensus panel of experts. Arch Intern Med. 2003;163:2716-2724.
35. Gore M, Dukes E, Rowbotham D, Tai K-S, Leslie DL. Prevalence of contraindicated medical conditions and use of precluded medications in patients with painful neuropathic disorders prescribed amitriptyline. Pain Pract. 2006;6:265-272.
36. ® [Duloxetine Hydrochloride] Delayed Release Capsules Prescribing Information. Indianapolis, IN: Eli Lilly and Company; 2011.
37. ® [Pregabalin] Capsules Prescribing Information. New York, NY: Pfizer, Inc.; 2011.
38. Margolis J, Cao Z, Fowler R, et al. Evaluation of healthcare resource utilization and costs in employees with pain associated with diabetic peripheral neuropathy treated with pregabalin or duloxetine. J Med Econ. 2010;13:738-747.
39. Burke JP, Sanchez RJ, Joshi AV, Cappelleri JC, Kulakodlu M, Halpern R. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine. Pain Pract. 2011;12:209-218.
40. Gore M, Zlateva G, Tai KS, Chandran AB, Leslie D. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care. Pain Pract. 2011;11:167-179.
41. Hovaguimian A, Gibbons CH. Clinical approach to the treatment of painful diabetic neuropathy. Ther Adv Endocrinol Metab. 2011;2:27-38.